Clinical Trial Update: Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating Blmf, Lenalidomide, and Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Blmf
• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Hellenic Society of Hematology | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING